Tenpoint: a toolbox of ex vivo and in vivo treatments for vision loss

Tenpoint emerged from stealth on Wednesday with $70 million, including a $62 million series A led by F-Prime Capital, Sofinnova Partners and British Patient Capital, and a toolbox of ex vivo stem cell and in vivo cell reprogramming approaches to treat vision loss. 

Cambridge, U.K.-based Tenpoint Therapeutics Ltd. is developing an ex vivo platform based on the surgical implantation of stem cells and an in vivo cell reprogramming platform based on the targeted administration of transcription factors. Both platforms were invented by the company’s scientific co-founders to treat vision loss...